ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

gilteritinib

Also written as “Gilteritinib”, “ASP2215” and “gilteritinib mini tablet”.

Its studies are mostly in Leukemia, Myeloid, Acute · Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Drug pageGilteritinib: every studyAll 41 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 16, 201520 company-led studies, 2 open or runningNext primary completion: Jul 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharmaits history only182 open or runningphase 3since Apr 16, 2015Nov 6, 2013Jul 31, 2028phase 2 · NCT05520567
AbbVieits history only10 open or runningphase 1since Aug 8, 2018Aug 8, 2018none ahead
Bristol-Myers Squibb10 open or runningphase 1since Mar 26, 2020Mar 26, 2020none ahead

Also a collaborator on its studies: Hoffmann-La Roche.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 26, 2020First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT04336982 · 22 enrolled · United States, Belgium, Canada and more

TargetBeta

“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), ”NCIt, by rule
“Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor”ChEMBL 37, by rule

Studies

The one study Bristol-Myers Squibb leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04336982Leukemia, Myeloid, Acute · United States, Belgium, Canada and more1TerminatedOct 25, 202322

How it is read

Names in the registry

  • “Gilteritinib”, 11 entries
  • “gilteritinib”, 7 entries
  • “ASP2215”, 1 entry
  • “gilteritinib mini tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.